Table 1.

Effects of Therapy with PHA-739358 on the Growth of Human HCCs Xenografted in NOD/SCID Mice.

Experiment	Initial Volume (mm3)	Final Volume (mm3)	Final (% Growth)	Tumor Weight (mg)
Setting 1
Control (Huh-7)	60.7 ± 43.2	1182.9 ± 687.6	2175 ± 1839	1298 ± 712
PHA-739358 (Huh-7)	52.5 ± 32.4	232.1 ± 211.2†	340 ± 307†	366 ± 333*
Control (HepG2)	111.6 ± 62.7	908.7 ± 621.1	873 ± 250	1484 ± 1046
PHA-739358 (HepG2)	106.0 ± 80.7	106.4 ± 39.6‡	137 ± 72‡	119 ± 34‡
Setting 2
Control	291.3 ± 285.7	Treatment stopped on day 12 owing to high tumor volume
PHA-739358 1 x 15 mg/kg	245.6 ± 239.0	680.7 ± 421.9¶	391 ± 122¶	1183 ± 1021#
Sorafenib 1 x 10 mg/kg	212.1 ± 179.9	704.4 ± 644.2¶	454 ± 216¶	1326 ± 1078#
Combination	243.0 ± 139.7	256.4 ± 256.9¶	97 ± 64¶,§	281 ± 612#

Setting 1: Monotherapy of PHA-739358 at the standard dosage of 2 x 15 mg/kg per day.

Setting 2: Combination therapy of PHA-739358 at a reduced dosage with sorafenib.

Values were presented as mean ± SD.

^*P < .05 versus controls.

^†P < .01 versus controls.

^‡P < .001 versus controls.

^§P < .01 versus PHA-739358 and versus sorafenib, respectively.

^¶Final volumes in Setting 2 were obtained on day 20 when treatment was stopped.

^#Tumor weights were obtained after killing on day 24.